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Abstract 
 
Background: It has been suggested that the measles, mumps, and rubella vaccine (MMR) is a cause of 
regressive autism. Mumps, measles and rubella are serious diseases that can lead to potentially fatal illness, 
disability and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant 
drop in vaccination coverage in several countries persists, despite its almost universal use and accepted 
effectiveness. The cause of autism is unclear, vaccines have been incriminated. The aim of this study was the 
critical appraisal of the literature reporting association between Measles-Mumps-Rubella Vaccine (MMR) and 
autism.  
Methods: PubMed was searched for systematic reviews (SRs), meta-analysis, observation studies, of association 
between MMR and autism published from January 2006 through February 2016. In the present study we 
focused to assess the scientific validity and quality of published article. Guidelines and assessment tools we 
used to provide a structured approach to the process of critical appraisal follow the check compliance PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement for meta-analysis or 
systematic review and STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 
Explanation and Elaboration document for observational studies. 
Results: The search identified 18 eligible article included in two SRs, two meta-analysis, ten OS.  Eleven items 
/sub-items (PRISMA) were reported by more than 75% of SRs, meta-analysis and 14 items/sub-items (STROBE) 
were reported by more than 70% of OS. Some essential methodological aspects of SRs, meta-analysis and OS 
(such as risk of bias, effect estimates, absolute risks, missing data and flow diagram) were underreported. 
Conclusion: The total of the meta-analysis, the systematic review and the observational studies have found no 
evidence for the link between vaccination and the subsequent risk of developing autism or autistic spectrum 
disorder. The quality of reporting in meta-analysis systematic review and observational studies in MMR and 
autism was considered satisfactory, although certain items were underreported. 
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Introduction 
 
Autism is a developmental disorder characterized by impaired social interaction, difficulty with verbal and 
nonverbal communication, and limited activities and interests (NINDS 2006). Although autism was first described 
by American psychiatrist Leo Kanner 1-3 in 1943 the cause and treatment of this brain disorder still remains poorly 
understood. The Diagnostic and Statistical Manual of Mental Disorders (DSM –IV) classifies autism as one disease 
in a class of developmental disorders referred to as autism spectrum disorders (ASDs) or pervasive 
developmental disorders (PDDs) (Strock 2007, NINDS 2006). Asperger syndrome, Rett syndrome, childhood 
disintegrative disorder, and pervasive developmental disorder not otherwise specified along with autism make 
up the ASDs. Autism is the most common of the ASDs.  The etiology of ASD is unknown, although both genetic 
and environmental factors play a causative role 4-6. Now, autism is no longer regarded as a simple developmental 
disorder but rather a biological disorder of complex etiology and heterogeneity 7-10, with evidence of 
developmental delay within the first 3 years of life. Typically, autism is characterized by “qualitative deficits” in 4 
major categories: 1) deficits of developmental rates and/or profiles, 2) deficits of responses to sensory stimuli, 3) 
deficits of speech, language and communication capabilities, and 4) deficits of social interactions and/or manners 
of relating to other people. Although the diagnosis of autism is made during early childhood, the disorder 
continues to persist well into adulthood, eventually becoming a lifelong neuro disability. 
Vaccines are considered one of the greatest public health achievements of the 20th century. Vaccinations have 
significantly reduced or abolished numerous communicable diseases that used to harm or kill many people. Yet, 
those infectious diseases can still occur in people who are not protected by the immunizations, so the reason for 
widespread use of vaccinations is clearly evident. Measles, mumps and rubella (MMR) are serious diseases that 
can lead to potentially fatal illnesses, disabilities and death. MMR are particularly prevalent in low-income 
countries where vaccination programs are inconsistent and the mortality rate from disease is high. However, in 
high-income countries MMR are now rare, due to large-scale vaccination programs11-14. The single component 
live attenuated vaccines of MMR have been licensed in the USA since the 1960s COHRANE. These single vaccines 
have been shown to be highly effective at reducing the morbidity and mortality rates associated with these 
childhood illnesses. No national health policy recommends that the MMR vaccine be given as three separate 
vaccines. Combined live attenuated MMR vaccine was introduced in the USA in the 1970s. MMR is included in 
the World Health Organization’s Expanded Program on Immunization and it is used in over 50 European 
countries, the USA, Canada, Australia and New Zealand; in total, over 90 countries around the world use the 
MMR vaccine. Accepted recommendations are that the first dose should be administered on or after the first 
birthday and the second dose of MMR at least 28 days later. In many European countries the second dose is 
administered at four to 10 years of age15-18. 
Over the past several years much concern has been raised regarding the potential links of childhood 
vaccinations with the development of autism and autism spectrum disorders (ASD). The vaccinations that have 
received the most attention are the measles, mumps, rubella (MMR) vaccine and thimerosal-containing vaccines 
such as the diphtheria, tetanus, pertussis (DPT or DT) vaccine. Wakefield et al18 were the first to propose that 
administration of the measles, mumps, and rubella (MMR) vaccine may be causally related to the development 
of autism. A rising awareness of autism incidence, prevalence, and the postulated causation of childhood 
vaccinations has led to both an increased distrust in the trade-off between vaccine benefit out-weighing 
potential risks and an opportunity for disease resurgence. Vaccine-preventable diseases clearly still hold a 
presence in modern day society and the decision to opt out of MMR or other childhood vaccination schedules 
because of concerns regarding the development of autism should be properly evaluated with avail-able 
evidence. MMR vaccination is a requirement for entry into schools, so any increase in adverse events associated 
with the vaccine carries widespread public health importance.  
The objective of this study was the critical appraisal of the literature reporting association between Measles-
Mumps-Rubella Vaccine (MMR) and autism. This is a systematic process that was used to identify the strengths 
and weaknesses of research articles in order to assess the usefulness and validity of the research findings. 
Although the methodological criteria by which the validity of a study is assessed vary according to its design, 
some general principles underpin the evaluation of any research study. 
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Methods 
 
Data Sources, Search Strategies and Studies Selection 
Literature for this review was systematically identified by searching PubMed for papers published between 
January 2006 and February 2016. The search was limited to the following criteria: "English" language, "Humans" 
species, and as a search criterion the following term: "measles-mumps-rubella" And "autism (i.e., to appear in 
the title – checking by MESH). The search strategy included Clinical Trials (CTs): "meta-analyses", "systematic 
reviews" (SRs), “randomized controlled trials” (RCTs), ‘‘observational studies” (OS i.e., cohort, case control, and 
cross-sectional).  An SR or meta-analysis was considered eligible when it were published in a peer-reviewed 
journal and provided the complete list of references of all articles included in the SR or meta-analysis. These 
articles were eligible if they had been published as full papers or short reports in a regular issue or supplement 
of peer-reviewed journals indexed in PubMed. Articles published as editorials, letters, conferences or meeting 
abstracts were excluded.  In the study, were include article which refer to the link between MMR and autism. The 
articles excluded because studied other factors of correlation. 
Data Extraction and Reporting Assessment Tool 
In the present study we focused to assess the scientific validity and quality of published Clinical Trials (CTs). The 
first question to ask in any research article is whether its topic is relevant to field of study and if the article add 
new ideas and knowledge the scientific research endeavor. The fundamental task of critical appraisal is to identify 
the specific research question that an article addresses, as this process will determine the optimal study design. 
Furthermore, the questions to be answered when evaluating are if the study design is appropriate for the 
research question and if the study methods address the key potential sources of bias (Table 1). This process μας 
enables to assess the study's usefulness and whether its findings are trustworthy. The criteria used to assess the 
validity and relevance of scientific literature, vary according to its design of research study.  
Guidelines and assessment tools we used to provide a structured approach to the process of critical appraisal 
follow the check compliance PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
statement for meta-analysis or systematic review and STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) Explanation and Elaboration document for observational studies. The checklist in the 
PRISMA includes 27 items pertaining to the content of a systematic review and meta-analysis, which include the 
title, abstract, methods (twelve items), results (seven items), discussion (three items) and funding. Respectively, 
the checklist in the STROBE includes 22 items pertaining to the content of Observational Studies, which include 
the title, abstract, methods (nine items), results (five items), discussion (four items) and funding. All items were 
investigated in terms of whether they were reported, not whether they were actually carried out during the study. 
Items were to be scored as ‘‘yes’’ if they were reported in enough detail to allow the reader to judge that the 
definition had been met. Especially in the case of matching criteria, the item was coded as ‘‘yes’’ only when the 
matching procedure was explicitly described (i.e., the number of controls per case was specified and the matching 
variables were clearly stated). Alternative responses (apart from ‘‘yes’’ or ‘‘no’’) and unclear responses to each 
question were coded as negative responses. 
In order to clarify whether an article will be included or not from the study we used the flow diagram. It depicts 
the flow of information and maps out information about the number of records identified in the literature 
searches, the number of studies included and excluded, and the reasons for exclusions. Then, we focused of 
recording of the findings. In order to clarify whether an article is supporting or not the correlation of MMR to 
autism.  
 
 
Selected Abbreviations and Acronyms 
STROBE =Strengthening the Reporting of Observational Studies in Epidemiology 
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
SRs = Systematic Reviews 
OS = Observational Studies 
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Methodological Evaluation 
The evaluation of articles both in systematic reviews, meta-analysis and in observations studies were restricted 
to items concerning the methods and results sections.   
The PRISMA statement: methodological items refer to the reporting of protocol and registration, study 
characteristics (e.g. PICOS, length of follow-up, years considered, language, publication status) and report 
characteristics (e.g. years considered, language, publication status), the electronic search strategy, the list and 
define all variables for which data were sought, the describe of methods used for assessing risk of bias of 
individual studies (e.g. risk ratio, difference in means), data collection process and data items (e.g. databases with 
dates of coverage, contact with study authors to identify additional studies), any efforts to address potential 
sources of bias, risk of bias in individual studies and risk of bias across studies, the principal summary measures, 
synthesis of results and additional analyses (e.g. sensitivity or subgroup analyses, meta-regression). Furthermore, 
the items in the results section refer to the reporting of study selection and study characteristics (give numbers 
of studies screened, assessed for eligibility), and included in the review with reasons for exclusions at each stage, 
ideally with a flow diagram and for each study, present characteristics for which data were extracted, results of 
individual studies (results of individual studies and effect estimates and confidence intervals, ideally with a forest 
plot), synthesis of results (present results of each meta-analysis done, including confidence intervals and 
measures of consistency), additional analysis (results of additional analyses).   
The STROBE statement: methodological items refer to the reporting of study design, setting of the study, 
participants’ information (eligibility criteria, sources and methods of selection, or matching criteria if relevant), 
definition of all variables used, data sources and methods of measurement, any efforts to address potential 
sources of bias, study size, handling of quantitative variables in the study and performed statistical methods (i.e. 
methods used to control for confounding and to examine subgroups and interactions, methods of handling 
missing data or how loss to follow-up was addressed, methods of matching of cases and controls, analytical 
methods taking account of sampling strategy and any description of sensitivity analysis). Furthermore, the items 
in the results section refer to the reporting of participants’ information (numbers of individuals at each stage of 
the study, reasons for nonparticipation at each stage, use of flow diagram), descriptive data (characteristics of 
study participants, numbers of participants with missing data, summary of follow-up time), outcome data 
(numbers of outcome events or summary measures), main results (unadjusted or confounder-adjusted estimates 
and their precision, presentation of 95% confidence intervals, category boundaries when continuous variables 
were categorized and translation of estimates of relative risk to absolute risk for a meaningful time period), and 
other analyses done (e.g. analyses of subgroups and interactions, and sensitivity analyses).  
 
 
Table 1. Basic Questions for Ask when Critically Appraising a Research Article 
Does the study add anything new? 
What type of research question is being asked? 
Was the study design appropriate for the research question? 
Did the study methods address the most important potential sources of bias? 
Was the study performed according to the original protocol? 
Does the study test a stated hypothesis? 
Were the statistical analyses performed correctly? 
Do the data justify the conclusions? 
Are there any conflicts of interest? 
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Table 2. Frequency of reporting of the items in the PRISMA statement, overall and in each systematic review and 
meta-analysis. 
 
Section / topic # Checklist item n (%) 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  4(100%) 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
4(100%) 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4(100%) 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4(100%) 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
4(100%) 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
4(100%) 
Information sources  7 Describe all information sources in the search and date last searched.  4(100%) 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
3(75%) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
3(75%) 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
3(75%) 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
3(75%) 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies and how this information is to be 
used in any data synthesis.  
2(50%) 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  3(75%) 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency for each meta-analysis. 
3(75%) 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence.  2(50%) 
Additional analyses  16 Describe methods of additional analyses, if done, indicating which were pre-specified.  2(50%) 
RESULTS 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
1(25%) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
4(100%) 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment. 2(50%) 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
2(50%) 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  2(50%) 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies   2(50%) 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression  3(75%) 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
4(100%) 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
2(50%) 
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
3(75%) 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
3(75%) 
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Table 3. Frequency of reporting of the items in the STROBE statement, observational studies 
  
Section / 
topic 
# Checklist item n  (%) 
TITLE  
 1 a. Indicate the study’s design with a commonly used term in the title or the abstract 9 (90%) 
b. Provide in the abstract an informative and balanced summary of what was done and what was found 10 (100%) 
INTRODUCTION 
 
Rationale 2 Explain the scientific background and rationale for the investigation being reported 10 (100%) 
Objectives 3 State specific objectives, including any prespecified hypotheses 8 (80%) 
METHODS  
Study design 4 Present key elements of study design early in the paper 8 (80%) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and 
data collection 
8 (80%) 
Participants 6 
   
 
 
      
a. Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants.  
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment     
and control selection. 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
6 (60%) 
b. Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.  7 (70%) 
Data sources 8  For each variable of interest, give sources of data and details of methods of assessment.  5 (50%) 
Bias 9 Describe any efforts to address potential sources of bias 3 (30%) 
Study size 10 Explain how the study size was arrived at 6 (60%) 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses.  2 (20%) 
Statistical 
methods 
12 a. Describe all statistical methods, including those used to control for confounding 8 (80%) 
b. Describe any methods used to examine subgroups and interactions  
c. Explain how missing data were addressed  
d. Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
   Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
 
e. Describe any sensitivity analyses  
 
RESULTS  
Participants 13 a. Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed 
4 (40%) 
b. Give reasons for non-participation at each stage  
c. Consider use of a flow diagram  
Descriptive 
data 
14 a. Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and 
potential confounders 
8 (80%) 
b. Indicate number of participants with missing data for each variable of interest  
c. Cohort study—Summarize follow-up time (e.g., average and total amount)  
Outcome data 15 Cohort study—Report numbers of outcome events or summary measures over time 8 (80%) 
Case-control study—Report numbers in each exposure category, or summary measures of exposure  
Cross-sectional study—Report numbers of outcome events or summary measures  
Main results 16 a. Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% 
confidence interval).  
5 (50%) 
b. Report category boundaries when continuous variables were categorized  
c. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses 6 (60%) 
DISCUSSION  
Key results 18 Summarize key results with reference to study objectives 10 (100%) 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 9 (90%) 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence 
7 (70%) 
General is 
ability 
21 Discuss the general is ability (external validity) of the study results 5 (50%) 
FUNDING 
 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original 
study on which the present article is based 
7 (70%) 
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Results 
Eligible Studies 
Our search strategy identified 289 potentially eligible studies involving the association between measles-
mumps-rubella vaccine and autism, of which fourteen met the inclusion criteria (Fig. 1). The fourteen articles 
were published during the period from January 2006 through February 2016. A full list of the reports that were 
retrieved as full-text and included in the final analysis is found in the end of paper (Table 4). Were excluded 
immediately on inspection of the abstracts and title as they clearly did not meet inclusion criteria 36 papers 
(twenty article comment, letter and editorial, five historical article, four article news-paper, twelve review) (Table 
5), leaving 53 papers whose methods sections were analyzed in more detail to determine suitability. Further, 39 
full-text articles excluded because studied other factors of correlation, leaving fourteen article with usable 
information were included in this study. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram of citations through the retrieval and screening process 
 
PudMed identified 289 
article 
 
Limits:  
Publication dates, 10 years (n=104) 
Species, Humans (n=99) 
Languages, English (n=89) 
 
 
Studies excluded after inspection of abstracts 
(n=36) 
20 article Comment, Letter and Editorial, 
Historical Article 
4 Article News 
12 Review 
 
 
 
 
 
 
Studies with usable 
information, by 
outcome (n=14) 
Full-text articles 
excluded because 
studied other factors of 
correlation (n =39) 
 
Studies retrieved for more detailed 
evaluation (n =53) 
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The fourteen eligible studies including: two meta-analysis (eight cohort studies, eight case-control studies, two 
time-series studies, two self-controlled case), two systematic review (six ecological studies, four retrospective 
observational studies, five prospective observational studies, four population studies), ten observation studies 
(eight case control studies, two cohort study). (Fig. 2) 
 
  
 
 
 
 
 
 
 
 
 
Figure 2. Flow diagram of citations through the retrieval and screening process 
 
Main Results 
This critical appraisal of two meta-analysis, two systematic review and ten observation studies data has found 
no evidence for the link between vaccination and the subsequent risk of developing autism or autistic spectrum 
disorder. 
PRISMA was used for critical appraisal purposes of systematic review and meta-analysis. The checklist included 
27 items pertaining to the content of a systematic review and meta-analysis, which include the title, abstract, 
methods, results, discussion and funding.  These key questions were used to assess the validity and relevance of 
a research article. Also, assisted to identify the most relevant, high-quality studies that are available to guide 
their clinical practice. Overall, four items /sub-items (three and one items/subitems in methods and results 
sections, respectively) were reported by 100% of the studies (see Table 2).  In methods, the items include the 
presentation of: 1) the key elements of protocol design and registration, 2) the eligibility criteria for participants 
(PICOS, length of follow-up, years considered, language, publication status) and 3) the information sources (e.g. 
databases with dates of coverage, contact with study). In results, the item include the presentation of the 
presentation of the study selection. Furthermore, seven items/sub-items (including the four items already 
mentioned above) were reported by 75% (three of four) of the studies. The six additional items were 1) the 
electronic search strategy, 2) study selection (i.e. screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis), 3) the method of data extraction from reports, 4) list and define all 
variables for which data were sought, 5) the principal summary measures (e.g. risk ratio, difference in means), 6) 
the synthesis of results and 7) the reporting of risk of bias across studies. In results, (including the four items 
already mentioned above) the item include the presentation of the results of additional analyses. In contrast, 
some items were reported only by a small fraction of articles. For example, only two of four of articles provided 
the results of any assessment of risk of bias across studies or the results of each meta-analysis done, including 
confidence intervals and measures of consistency, data on risk of bias of each study and, if available, any outcome 
level assessment. Also, only two of four of articles provided all outcomes considered present, for each study: a) 
simple summary data for each intervention group, b) effect estimates and confidence intervals. The presentation 
2 meta-analysis  
n=74 
 
 
  
2 systematics review  
n=19 
 
Critical 
appraisal w  
 
10 observation studies 
 
8 cohort studies 
8 case-control studies 
2 time-series studies 
2 self controlled case 
series  
 
 
9 observational studies 
6 ecological studies  
4 population studies 
n= 8 case control studies 
n= 2 retrospective cohort 
study 
14 article retrieved as full text and 
included in final Critical appraisal
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of a flow diagram and reporting of absolute risk for a meaningful time period were very uncommon, refers to 
only one out of four of articles. 
Table 2 shows the results sections of the STROBE statement. Overall, five items/sub-items (three and two 
items/subitems in methods and results sections, respectively) were reported in eight of ten of the studies (Table 
3). In methods, the items include the presentation of: 1) the key elements of study design, 2) the setting, locations, 
relevant dates, including periods of recruitment, exposure, follow-up, and data collection and 3) the description 
of all statistical methods. In results, the items include: 1) descriptive data and 2) the details of outcome data. 
Furthermore, 11 items/sub-items (including the nine items already mentioned above) were reported in five or 
more of the studies. The six (four in methods and  two results sections) additional items were, 1) the eligibility 
criteria, and the sources and methods of selection of participants, 2) the clearly define all outcomes, exposures, 
predictors, potential confounders, and effect modifiers, 3) the sources of data and the details of methods of 
assessment and 4) explain how the study size was arrived at, 5) the main results, 6) the report other analyses 
done - e.g. analyses of subgroups and interactions, and sensitivity analyses. In contrast, some items were 
reported only by a small fraction of articles. For example, only two of ten of articles provided quantitative 
variables and only three of ten describe any efforts to address potential sources of bias. The presentation of a 
flow diagram and reporting of absolute risk for a meaningful time period were very uncommon, only four out of 
ten articles present it. 
 
Discussion 
After the publication of Andrew Wakefield’s research in 1998, which caused a great deal of confusion and 
debate, a lot of clinical researches were reported. In this paper, the majority of the researches come to a negative 
conclusion regarding the correlation between MMR and autism. Our analysis focused on the reporting of 
methodological items (items in method and results sections). In total, 14 articles published from January 2006 
through February 2016 were evaluated. This critical appraisal of two meta-analysis, two systematic review, eight 
case-control and two cohort studies has found no evidence for the link between vaccination and the subsequent 
risk of developing autism or autistic spectrum disorder (Table 3). 
 
Table 3. Studies that fail to support an association between MMR vaccine and autism. 
negative results / title of articles 
The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism 
spectrum disorder: the first case-control study in Asia. 
Measles vaccination and antibody response in autism spectrum disorders. 
Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum 
disorder. 
Response to measles-mumps-rubella vaccine in children with autism spectrum disorders. 
Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. 
Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: the results of a parent survey. 
Vaccines for measles, mumps and rubella in children. 
Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. 
Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination--United States, 2001-2010 
MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. 
Vaccines and the changing epidemiology of autism 
positive results/ title of articles 
Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. 
Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. 
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The quality of reporting in meta-analysis systematic review and observation studies in MMR and autism was 
considered satisfactory, although certain items were underreported. The present study investigated the scientific 
validity and quality of published reporting of MMR and autism, according to the STROBE and PRISMA statement. 
We concluded that most of these researches used the appropriate study for the research question and were 
performed according to the original protocol. However, the study methods didn’t address the most important 
potential of bias and any conflicts of interest. Still, the statistical analyses were performed correctly both in 
systematic statistical analyses and in OS. 
Although the overall reporting quality was relatively good (18 items/sub-items were reported by three of four 
the meta-analysis, systematic reviews and 14 items/sub-items were reported by 70% or more of the studies), 
there are some essential methodological aspects of meta-analysis and systematic reviews (such as risk of bias in 
individual studies, risk of bias across studies, flow diagram, synthesis of results) that are seldom reported, making 
it difficult for the reader to assess explicitly the validity of an OS, SRs and meta-analysis. Also, the observation 
studies there were some essential methodological aspects which were referred in fewer research (such as sources 
of bias and quantitative variables). 
There are several limitations to our study. We searched only in PubMed, which is the most common used 
medical database, for the eligible article and did not extent to the Cochrane Collaboration database to combine 
our results with one more sensitive search strategy. However, a more comprehensive literature search would be 
costly and time-consuming. In addition, trials which are difficultly retrieved tend to be of lower methodological 
quality and thus, bias could be introduced19. We considered only articles published in English, which could lead 
to language bias, since authors tend to publish article in English-language journals if the results are statistically. 
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Table 4. Article included 
 
 
 
 
 
PMID ΤITLE JOURNAL YEAR AUTHOR   
22521285 
The combined measles, mumps, and rubella vaccines 
and the total number of vaccines are not associated 
with development of autism spectrum disorder: the 
first case-control study in Asia. 
Vaccine 2012 Jun 13 Uno Y, Uchiyama T , 
Kurosawa M, Aleksic B,  
Ozaki N 
case–control 
study 
18252754 
Measles vaccination and antibody response in autism 
spectrum disorders. 
Arch Dis Child   2008 Oct Baird G1, Pickles A, Simonoff 
E, Charman T, Sullivan P, 
Chandler S, Loucas T, 
Meldrum D, Afzal M, Thomas 
B, Jin L, Brown D. 
case–control 
study 
25562790 
Early exposure to the combined measles-mumps-
rubella vaccine and thimerosal-containing vaccines 
and risk of autism spectrum disorder. 
Vaccine 2015 May 
15 
Uno Y, Uchiyama T, 
Kurosawa M, Aleksic B,  
Ozaki N 
case–control 
study  
23606694 
Response to measles-mumps-rubella vaccine in 
children with autism spectrum disorders. 
In Vivo 2013 May-
Jun 
Gentile I1, Bravaccio C, 
Bonavolta R, Zappulo E, 
Scarica S, Riccio MP, Settimi 
A, Portella G, Pascotto A, 
Borgia G 
case–control 
study  
19952979 
Lack of association between measles-mumps-rubella 
vaccination and autism in children: a case-control 
study 
Pediatr Infect Dis J. 2010 May Mrozek-Budzyn D1, Kiełtyka 
A, Majewska R 
case–control 
study   
18445737 
Acetaminophen (paracetamol) use, measles-mumps-
rubella vaccination, and autistic disorder: the results 
of a parent survey. 
Autism.  2008 May Schultz ST, Klonoff-Cohen 
HS, Wingard DL, Akshoomoff 
NA, Macera CA, Ji M 
case-control, 
study 
22336803 
Vaccines for measles, mumps and rubella in children. Cochrane Database 
Syst Rev 
2012 Feb 15 Demicheli V, Rivetti 
A, Debalini MG, Di 
Pietrantonj C 
metanalysis 
 
17015560 
No evidence of persisting measles virus in peripheral 
blood mononuclear cells from children with autism 
spectrum disorder. 
Pediatrics 2006 Oct D'Souza Y, Fombonne 
E, Ward BJ 
Systematic 
Review  
21592401 
Congenital rubella syndrome and autism spectrum 
disorder prevented by rubella vaccination--United 
States, 2001-2010 
BMC Public Health. 2011 May 
19 
Berger BE, Navar-Boggan 
AM, Omer SB 
mathematici 
model  
24814559 
Vaccines are not associated with autism: an 
evidence-based meta-analysis of case-control and 
cohort studies. 
Vaccine. 2014 Jun 17 Taylor LE 1 , Swerdfeger 
AL 1 , Eslick GD  
meta-analysis  
 
25898051 
Autism occurrence by MMR vaccine status among 
US children with older siblings with and without 
autism. 
JAMA 2015 Apr 21 Jain A, Marshall J, Buikema 
A, Bancroft T, Kelly JP, 
Newschaffer CJ 
retrospective 
cohort study  
16865547 
MMR-vaccine and regression in autism spectrum 
disorders: negative results presented from Japan. 
J Autism Dev Disord. 2007 Feb Uchiyama T1, Kurosawa 
M, Inaba Y 
Observational 
studies 
 
19614825 
Autism and vaccination-the current evidence. J Spec Pediatr Nurs 2009 Jul Miller L,  Reynolds J Systematic 
Review 
 
19128068 
Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009 Feb 15 Gerber JS, Offit PA Systematic 
Review 
 
17928818 
Vaccines and autism: evidence does not support a 
causal association. 
Clin Pharmacol Ther. 2007 Dec DeStefano F1 Systematic 
Review 
 
16919130 
Vaccines and the changing epidemiology of autism Child Care Health 
Dev. 
2006 Sep Taylor B Systematic 
Review 
 
25086160 
Safety of vaccines used for routine immunization of 
U.S. children: a systematic review. 
Pediatrics  2014 Aug Maglione MA , Das 
L  , Raaen L  , Smith Α  , Chari 
R  , Newberry S   
Systematic 
Review  
26103708 
Epidemiologic and Molecular Relationship Between 
Vaccine Manufacture and Autism Spectrum Disorder 
Prevalence. 
Issues Law Med 2015  Deisher TA , Doan 
NV , Koyama K , Bwabye S  
Systematic 
Review  
19758536 
Phenotypic expression of autoimmune autistic 
disorder (AAD): a major subset of autism. 
Ann Clin Psychiatry 2009 Jul-
Sep 
Singh VK Observational 
studies 
 
21071320 
Closer look at autism and the measles-mumps-
rubella vaccine 
Hensley E1, Briars L.  2010 Nov-
Dec 
J Am Pharm Assoc  Systematic 
Review 
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Table 5. Article excluded 
 
PMID TITLE  REASON 
20142376  
Lancet retracts 12-year-old article linking autism to MMR vaccines. Biography, Historical 
Article, News 
17075042  A surprising METamorphosis: autism genetics finds a common functional variant. Comment 
26192352  
Answers regarding the link between vaccines and the development of autism: A question of 
appropriate study design, ethics, and bias. 
comment letter 
25898047  Promising forecast for autism spectrum disorders. Comment, Editorial 
21209060  Wakefield's article linking MMR vaccine and autism was fraudulent. Comment, Editorial 
17168157  Autism and MMR vaccination or thimerosal exposure: an urban legend? Comment, Editorial 
19176580  
A response to the article on the association between paracetamol/ acetaminophen :use and autism 
by Stephen T. Schultz. 
Comment, Letter 
18762548  Immunization uptake in siblings of children with autism. Comment, Letter 
26757474  
Correction of Description of MMR Vaccine Receipt Coding and Minor Errors in MMR Vaccine 
and Autism Study. 
Comment, Letter 
20432106  Setting the record straight: vaccines, autism, and the Lancet. Editorial 
10967744  MMR vaccine and autism. Editorial 
21985898  
Epidemiological designs for vaccine safety assessment: methods and pitfalls. Evaluation Studies, 
Review 
25947030  Immunizing against influenza is tricky   (Dummheit.) Historical Article 
21465869 Fallout of the enterocolitis, autism, MMR vaccine paper. Historical Article 
22930976  Lancet retracts study linking autism to MMR vaccine. Historical Article 
20222272  
Debunked. A pivotal paper linking vaccines and autism is retracted. Will the antivaccine movement 
go on? 
News 
18451989  Attention focuses on autism. News 
17923648  Vaccine autism link discounted, but effect of "study" is unknown News 
19200293  The rise in autism and the mercury myth. Research Support 
22848999  Credibility battles in the autism litigation. Research Support 
23324619  Vaccine administration and the development of immune thrombocytopenic purpura in children. Research Support 
25612664  
Spotlight on measles in Italy: why outbreaks of a vaccine-preventable infection continue in the 21st 
century. 
Other studies/reviews 
23449385 On alert for autism spectrum disorders. Other studies/reviews 
22108039  Acceptance on the move: public reaction to shifting vaccination realities. Other studies/reviews 
20653261  MMR vaccine and autism: is there a link Other studies/reviews 
20299908 Speak the language of autism. Other studies/reviews 
20030462  Did acetaminophen provoke the autism epidemic Other studies/reviews 
19015994  Autism overflows: increasing prevalence and proliferating theories. Other studies/reviews 
18771165  Update on autism and childhood vaccines Other studies/reviews 
19968949  Vaccines and autism: an update Other studies/reviews 
17894204 Autism and environmental influences: review and commentary. Other studies/reviews 
17181438  Postlicensure epidemiology of childhood vaccination: the Danish experience. Other studies/reviews 
17168158  Immunizations and autism: a review of the literature. Comment 
25523970  
Measles outbreak in Greater Manchester, England, October 2012 to September 2013:  
epidemiology and control. 
Other studies/reviews 
22428439  I've heard some things that scare me". Responding with empathy to parents' fears of vaccinations. Historical Article 
21560548 
Dilemmas of a vitalizing vaccine market: lessons from the MMR vaccine/autism debate Article studying other 
factors of correlation 
21387868  
Autism and vaccines: search for cause amidst controversy. Article studying other 
factors of correlation 
21343697  
MMR vaccination and autism: learnings and implications. Article studying other 
factors of correlation 
20944043  The autism-vaccine story: fiction and deception Review  
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 Increasing immunization coverage. Comment 
19266897  Autism and vaccinations: is there a correlation Comment 
19213289  Autism spectrum disorders: prevalence and vaccines. Comment 
18726760  
National vaccine injury compensation program: the potential impact of Cedillo for vaccine-related 
autism cases 
Article studying other 
factors of correlation 
18323140  
Autism: part I. Deficits, prevalence, symptoms, and environmental factors. Article studying other 
factors of correlation 
17898095  
Cases in vaccine court--legal battles over vaccines and autism. Article studying other 
factors of correlation 
17867721  
A case study of a graphical misrepresentation: drawing the wrong conclusions about the measles, 
mumps and rubella virus vaccine. 
Comment 
22879643  Advertising watchdog orders website to remove claims linking MMR vaccine with autism. News 
21878599  MMR vaccine and autism: vaccine nihilism and postmodern science. Comment 
25724821  Autism and vaccination: The value of the evidence base of a recent meta-analysis. meta-analysis 
23229992  Dispelling vaccine myths: MMR and considerations for practicing pharmacists. Systematic Review 
18019187  Update on autism and vaccines. Comment 
19006807  Another study on the safety of measles vaccine and risks of autism. Comment 
17595690  Child development. An unexpected effect of the autism-vaccine controversy. Comment 
24590751   
Article studying other 
factors of correlation 
25002000  
Childhood vaccine beliefs reported by Somali and non-Somali parents. Article studying other 
factors of correlation 
23045216  
Immunization uptake in younger siblings of children with autism spectrum disorder. Article studying other 
factors of correlation 
22230590  
U.K. parents' decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the 
MMR autism controversy: a qualitative analysis 
Article studying other 
factors of correlation 
17540488  
Children's health and the social theory of risk: insights from the British measles, mumps and rubella 
(MMR) controversy. 
Article studying other 
factors of correlation 
18019187  
Current controversies in the USA regarding vaccine safety. Article studying other 
factors of correlation 
26596077  
Addressing MMR Vaccine Resistance in Minnesota's Somali Community. Article studying other 
factors of correlation 
17395344  
Tracking mothers' attitudes to MMR immunisation 1996-2006. Article studying other 
factors of correlation 
19813430  
Parental vaccine concerns in Kentucky. Article studying other 
factors of correlation 
17376937  
MMR: marginalised, misrepresented and rejected? Autism: a focus group study. Article studying other 
factors of correlation 
18381512  
Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship 
to MMR immunization rates in the United State 
Article studying other 
factors of correlation 
22496631  
Evolutionary game theory and social learning can determine how vaccine scares unfold. Article studying other 
factors of correlation 
22063388  
Lessons from an online debate about measles-mumps-rubella (MMR) immunization. Article studying other 
factors of correlation 
 
22236220 
The blame frame: media attribution of culpability about the MMR-autism vaccination scare. Article studying other 
factors of correlation 
24857555  
Science, pseudoscience, and the frontline practitioner: the vaccination/autism debate. Article studying other 
factors of correlation 
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